Edgewise Therapeutics (EWTX) Accumulated Expenses (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Accumulated Expenses data on file, last reported at $8.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 115.27% year-over-year to $8.6 million; the trailing twelve-month figure through Mar 2026 stood at $8.6 million (up 115.27% YoY), and the FY2025 full-year result was $7.9 million, up 9.56% from the prior year.
• Accumulated Expenses climbed to $8.6 million in Q1 2026, from $7.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $8.6 million in Q1 2026 to a low of $1.3 million in Q1 2022.
• A 5-year average of $5.4 million and a median of $5.8 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 343.46% in 2023 and plunged 51.01% in 2024, its largest moves.
• Tracing EWTX's Accumulated Expenses over 5 years: stood at $5.8 million in 2022, then advanced by 3.96% to $6.1 million in 2023, then grew by 19.07% to $7.2 million in 2024, then grew by 9.56% to $7.9 million in 2025, then rose by 8.02% to $8.6 million in 2026.
• Business Quant data shows EWTX's Accumulated Expenses at $8.6 million in Q1 2026, $7.9 million in Q4 2025, and $6.5 million in Q3 2025.